Benzinga | Aug 10, 2020 07:44AM EDT

Pieris Pharmaceuticals Q2 EPS $(0.09) Beats $(0.17) Estimate, Sales $11.25M Beat $7.76M Estimate

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.17) by 47.06 percent. This is a 62.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $11.25 million which beat the analyst consensus estimate of $7.76 million by 44.92 percent. This is a 110.92 percent increase over sales of $5.33 million the same period last year.